1.	Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet. 2008;47(11):743-52.
2.	Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189-206.
3.	Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin Pharmacokinet. 1996;31(4):275-92.
4.	Open Systems Pharmacology - PBPK Model Library - Alfentanil [Internet]. 2020 [cited October 24, 2022]. Available from: https://github.com/Open-Systems-Pharmacology/Alfentanil-Model.
5.	Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, et al. PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin. CPT Pharmacometrics Syst Pharmacol. 2018;7(10):647-59.
6.	Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth. 1982;54(8):871-7.
7.	Meuldermans W, Van Peer A, Hendrickx J, Woestenborghs R, Lauwers W, Heykants J, et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology. 1988;69(4):527-34.
8.	Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther. 2001;70(6):505-17.
9.	Wandel C, Kim R, Wood M, Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002;96(4):913-20.
10.	Ferrier C, Marty J, Bouffard Y, Haberer JP, Levron JC, Duvaldestin P. Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology. 1985;62(4):480-4.
11.	Open Systems Pharmacology - PBPK Model Library - Caffeine [Internet]. 2019 [cited October 24, 2022]. Available from: https://github.com/Open-Systems-Pharmacology/Example_Caffeine.
12.	Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, et al. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam. CPT Pharmacometrics Syst Pharmacol. 2019;8(5):296-307.
13.	Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol. 1981;21(1):45-52.
14.	Busto U, Bendayan R, Sellers EM. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet. 1989;16(1):1-26.
15.	Brachtel D, Richter E. Absolute bioavailability of caffeine from a tablet formulation. J Hepatol. 1992;16(3):385.
16.	Grzegorzewski J, Bartsch F, Köller A, König M. Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing. Front Pharmacol. 2021;12:752826.
17.	Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 1983;24(1):93-8.
18.	Lelo A, Birkett DJ, Robson RA, Miners JO. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol. 1986;22(2):177-82.
19.	Arnaud M. Metabolism of caffeine and other components of coffee.  Caffeine, Coffee and Health. New York: Raven Press; 1993.
20.	Desmond PV, Patwardhan RV, Johnson RF, Schenker S. Impaired elimination of caffeine in cirrhosis. Dig Dis Sci. 1980;25(3):193-7.
21.	Lewis FW, Rector WG, Jr. Caffeine clearance in cirrhosis. The value of simplified determinations of liver metabolic capacity. J Hepatol. 1992;14(2-3):157-62.
22.	Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707-24.
23.	Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55(2):236-42.
24.	Wright C, Downing J, Mungall D, Khan O, Williams A, Fonkem E, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol. 2013;4:192.
25.	Sinha J, Karatza E, Gonzalez D. Physiologically-based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents. CPT Pharmacometrics Syst Pharmacol. 2022;11(2):225-39.
26.	Radtke RA. Pharmacokinetics of Levetiracetam. Epilepsia. 2001;42(s4):24-7.
27.	Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85(2):77-85.
28.	Coupez R, Nicolas JM, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia. 2003;44(2):171-8.
29.	Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther. 2005;77(6):529-41.
30.	Open Systems Pharmacology - PBPK Model Library - Metoprolol [Internet]. 2020 [cited October 24, 2022]. Available from: https://github.com/Open-Systems-Pharmacology/Metoprolol-Model.
31.	Rüdesheim S, Wojtyniak JG, Selzer D, Hanke N, Mahfoud F, Schwab M, et al. Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics. 2020;12(12).
32.	Kirchheiner J, Heesch C, Bauer S, Meisel C, Seringer A, Goldammer M, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2004;76(4):302-12.
33.	Plosker GL, Clissold SP. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs. 1992;43(3):382-414.
34.	Jordö L, Attman PO, Aurell M, Johansson L, Johnsson G, Regårdh CG. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet. 1980;5(2):169-80.
35.	Regårdh CG, Jordö L, Ervik M, Lundborg P, Olsson R, Rönn O. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet. 1981;6(5):375-88.
36.	Open Systems Pharmacology - PBPK Model Library - Midazolam [Internet]. 2022 [cited October 24, 2022]. Available from: https://github.com/Open-Systems-Pharmacology/Midazolam-Model.
37.	Fresenius Kabi. Midazolam Package Insert. 2017.
38.	Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol. 1981;19(4):271-8.
39.	Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol. 2015;79(2):278-85.
40.	Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, et al. In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol. 2009;67(4):445-54.
41.	Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59(5):491-502.
42.	MacGilchrist AJ, Birnie GG, Cook A, Scobie G, Murray T, Watkinson G, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut. 1986;27(2):190-5.
43.	Pentikäinen PJ, Välisalmi L, Himberg JJ, Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 1989;29(3):272-7.
44.	Andersen V, Pedersen N, Larsen NE, Sonne J, Larsen S. Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice. Br J Clin Pharmacol. 2002;54(2):120-4.
45.	Dallmann A, Ince I, Coboeken K, Eissing T, Hempel G. A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. Clin Pharmacokinet. 2018;57(6):749-68.
46.	Taburet AM, Singlas E, Colin JN, Banzet O, Thibonnier M, Corvol P. Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects. Hypertension. 1983;5(4 Pt 2):Ii29-33.
47.	Ene MD, Roberts CJ. Pharmacokinetics of nifedipine after oral administration in chronic liver disease. J Clin Pharmacol. 1987;27(12):1001-4.
48.	Open Systems Pharmacology Community. Open Systems Pharmacology - PBPK Model Library - Omeprazole. 2022.
49.	Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Mantilla JDG, et al. A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. Pharmaceutics. 2020;12(12).
50.	Cederberg C, Andersson T, Skånberg I. Omeprazole: Pharmacokinetics and Metabolism in Man. Scandinavian Journal of Gastroenterology. 1989;24(sup166):33-40.
51.	Andersson T, Olsson R, Regårdh CG, Skånberg I. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. Clin Pharmacokinet. 1993;24(1):71-8.
52.	Piqué JM, Feu F, de Prada G, Röhss K, Hasselgren G. Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. Clin Pharmacokinet. 2002;41(12):999-1004.
53.	Rinetti M, Regazzi MB, Villani P, Tizzoni M, Sivelli R. Pharmacokinetics of omeprazole in cirrhotic patients. Arzneimittelforschung. 1991;41(4):420-2.
54.	Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57.
55.	Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005;100(2):131-8.
56.	Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):5s-12s.
57.	Pfizer. Revatio Product Monograph - Sildenafil Oral Suspension. 2014.
58.	Open Systems Pharmacology - PBPK Model Library - Sildenafil [Internet]. 2022 [cited October 24, 2022]. Available from: https://github.com/Open-Systems-Pharmacology/Sildenafil-Model.
59.	Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):21s-30s.
60.	Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188(8):901-6.
61.	Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J. 1995;8(4):637-42.
62.	Polosa R, Blackburn MR. Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends Pharmacol Sci. 2009;30(10):528-35.
63.	Open Systems Pharmacology - PBPK Model Library - Theophylline [Internet]. 2019 [cited October 24, 2022]. Available from: https://github.com/Open-Systems-Pharmacology/Theophylline-Model.
64.	Butts JD, Secrest B, Berger R. Nonlinear theophylline pharmacokinetics. A preventable cause of iatrogenic theophylline toxic reactions. Arch Intern Med. 1991;151(10):2073-7.
65.	Ogilvie RI. Clinical pharmacokinetics of theophylline. Clin Pharmacokinet. 1978;3(4):267-93.
66.	Simons KJ, Simons FE, Briggs CJ, Lo L. Theophylline protein binding in humans. J Pharm Sci. 1979;68(2):252-3.
67.	Froomes PR, Morgan DJ, Smallwood RA, Angus PW. Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis. Gastroenterology. 1999;116(4):915-20.